Endothelial Arf6 sustains electrical signaling and cerebral blood flow in mice through PIP <sub>2</sub> -dependent activation of Kir2.1 channels
Abstract
Brain capillaries sense neural activity and direct blood flow to active regions—a process termed neurovascular coupling that underlies activity-dependent increases in local perfusion (functional hyperemia). A key contributor to functional hyperemic responses is the capillary endothelial cell (cEC) inward rectifier K + (Kir2.1) channel, which, when activated by neuronal activity–derived extracellular K + , initiates vasodilatory electrical signals that propagate through the vascular network. Kir2.1 channel function requires continual production of its lipid cofactor, phosphatidylinositol-4,5-bisphosphate (PIP 2 ), and is compromised in mouse models of cerebral small vessel (cSVD). Although decreased PIP 2 availability is a common feature of cSVDs, mechanisms underlying PIP 2 synthesis remain poorly understood. We hypothesized that Arf6, a small GTPase expressed in cECs that stimulates PIP 2 production, is critical for this process. Using patch-clamp electrophysiology, we demonstrate that inhibiting Arf6 activity progressively decreased cEC Kir2.1 channel activity. This deficit manifested as loss of capillary-to-arteriole electrical signaling in isolated vessels and diminished functional hyperemia in vivo. Exogenously provided PIP 2 restored Kir2.1 currents and functional hyperemia after Arf6 inhibition or genetic knockdown. Collectively, our data suggest that cEC Arf6 sustains Kir2.1 activity by maintaining PIP 2 levels and demonstrate that diminished PIP 2 synthesis is sufficient to impair functional hyperemia. Furthermore, we identify Arf6 as a mechanistic link between PIP 2 production and endothelial electrical signaling, highlighting Arf6 as a potential therapeutic target for restoring functional hyperemia.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (12)
Maria F. Noterman-Soulinthavong
Department of Pharmacology, University of Vermont
María Sancho
Department of Pharmacology, University of Vermont
Saúl Huerta de la Cruz
Department of Pharmacology, University of Vermont
Michael Yarboro
Department of Pharmacology, University of Vermont
Maurizio Mandalà
Department of Pharmacology, University of Vermont
Masayo Koide
Department of Pharmacology, University of Vermont
Nathalie Beaufort
Department of Translational Stroke and Dementia Research, Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-Universität
Katalin Todorov-Völgyi
Department of Translational Stroke and Dementia Research, Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-Universität
Emma Moreland
Department of Pharmacology, University of Vermont
David Hill-Eubanks
Department of Pharmacology, University of Vermont
Martin Dichgans
Mark T. Nelson
Department of Pharmacology, University of Vermont